{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T12:36:46Z","timestamp":1767962206064,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T00:00:00Z","timestamp":1340323200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1038\/leu.2012.169","type":"journal-article","created":{"date-parts":[[2012,6,22]],"date-time":"2012-06-22T06:40:04Z","timestamp":1340347204000},"page":"130-135","source":"Crossref","is-referenced-by-count":11,"title":["SOCS2 is dispensable for BCR\/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function"],"prefix":"10.1038","volume":"27","author":[{"given":"N","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"\u00c5gerstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Wahlestedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Landberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Askmyr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ehinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Lilljebj\u00f6rn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Johnels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ishiko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J V","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W S","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Bryder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"J\u00e4r\u00e5s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Fioretos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,22]]},"reference":[{"key":"BFleu2012169_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"R Ren","year":"2005","unstructured":"Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005; 5: 172\u2013183.","journal-title":"Nat Rev Cancer"},{"key":"BFleu2012169_CR2","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1182\/blood.V97.5.1442","volume":"97","author":"S Li","year":"2001","unstructured":"Li S, Gillessen S, Tomasson MH, Dranoff G, Gilliland DG, Van Etten RA . Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR\/ABL. Blood 2001; 97: 1442\u20131450.","journal-title":"Blood"},{"key":"BFleu2012169_CR3","doi-asserted-by":"publisher","first-page":"8852","DOI":"10.1038\/sj.onc.1206892","volume":"22","author":"DM Dinulescu","year":"2003","unstructured":"Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW et al. c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene 2003; 22: 8852\u20138860.","journal-title":"Oncogene"},{"key":"BFleu2012169_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/ng.389","volume":"41","author":"Y Chen","year":"2009","unstructured":"Chen Y, Hu Y, Zhang H, Peng C, Li S . Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 2009; 41: 783\u2013792.","journal-title":"Nat Genet"},{"key":"BFleu2012169_CR5","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.4161\/cc.8.21.9852","volume":"8","author":"Y Chen","year":"2009","unstructured":"Chen Y, Li D, Li S . The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia. Cell Cycle 2009; 8: 3488\u20133492.","journal-title":"Cell Cycle"},{"key":"BFleu2012169_CR6","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1182\/blood-2005-09-3596","volume":"107","author":"A Hoelbl","year":"2006","unstructured":"Hoelbl A, Kovacic B, Kerenyi MA, Simma O, Warsch W, Cui Y et al. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood 2006; 107: 4898\u20134906.","journal-title":"Blood"},{"key":"BFleu2012169_CR7","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"EA Nelson","year":"2011","unstructured":"Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB et al. The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011; 117: 3421\u20133429.","journal-title":"Blood"},{"key":"BFleu2012169_CR8","doi-asserted-by":"publisher","first-page":"6188","DOI":"10.1038\/sj.onc.1204834","volume":"20","author":"S Xie","year":"2001","unstructured":"Xie S, Wang Y, Liu J, Sun T, Wilson MB, Smithgall TE et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001; 20: 6188\u20136195.","journal-title":"Oncogene"},{"key":"BFleu2012169_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/leu.2010.287","volume":"25","author":"A Samanta","year":"2011","unstructured":"Samanta A, Perazzona B, Chakraborty S, Sun X, Modi H, Bhatia R et al. Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 2011; 25: 463\u2013472.","journal-title":"Leukemia"},{"key":"BFleu2012169_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0303-7207(99)00175-6","volume":"158","author":"HW Davey","year":"1999","unstructured":"Davey HW, McLachlan MJ, Wilkins RJ, Hilton DJ, Adams TE . STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol Cell Endocrinol 1999; 158: 111\u2013116.","journal-title":"Mol Cell Endocrinol"},{"key":"BFleu2012169_CR11","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1182\/blood.V99.5.1766","volume":"99","author":"B Schultheis","year":"2002","unstructured":"Schultheis B, Carapeti-Marootian M, Hochhaus A, Weisser A, Goldman JM, Melo JV . Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 2002; 99: 1766\u20131775.","journal-title":"Blood"},{"key":"BFleu2012169_CR12","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","volume":"20","author":"C Zheng","year":"2006","unstructured":"Zheng C, Li L, Haak M, Brors B, Frank O, Giehl M et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia 2006; 20: 1028\u20131034.","journal-title":"Leukemia"},{"key":"BFleu2012169_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1002\/gcc.20528","volume":"47","author":"P H\u00e5kansson","year":"2008","unstructured":"H\u00e5kansson P, Nilsson B, Andersson A, Lassen C, Gullberg U, Fioretos T . Gene expression analysis of BCR\/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation. Genes Chromosomes Cancer 2008; 47: 267\u2013275.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFleu2012169_CR14","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.exphem.2008.11.003","volume":"37","author":"M J\u00e4r\u00e5s","year":"2009","unstructured":"J\u00e4r\u00e5s M, Johnels P, \u00c5gerstam H, Lassen C, Rissler M, Ed\u00e9n P et al. Expression of P190 and P210 BCR\/ABL1 in normal human CD34+ cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage. Exp Hematol 2009; 37: 367\u2013375.","journal-title":"Exp Hematol"},{"key":"BFleu2012169_CR15","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1073\/pnas.0510423103","volume":"103","author":"JP Radich","year":"2006","unstructured":"Radich JP, Dai H, Mao M, Oehler V, Schelter J, Druker B et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA 2006; 103: 2794\u20132799.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2012169_CR16","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.2415","volume":"17","author":"K Eppert","year":"2011","unstructured":"Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 2011; 17: 1086\u20131093.","journal-title":"Nat Med"},{"key":"BFleu2012169_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1073\/pnas.95.1.114","volume":"95","author":"DJ Hilton","year":"1998","unstructured":"Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, Sprigg NS et al. Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci USA 1998; 95: 114\u2013119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2012169_CR18","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/43213","volume":"387","author":"TA Endo","year":"1997","unstructured":"Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997; 387: 921\u2013924.","journal-title":"Nature"},{"key":"BFleu2012169_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/43219","volume":"387","author":"T Naka","year":"1997","unstructured":"Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997; 387: 924\u2013929.","journal-title":"Nature"},{"key":"BFleu2012169_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/43206","volume":"387","author":"R Starr","year":"1997","unstructured":"Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997; 387: 917\u2013921.","journal-title":"Nature"},{"key":"BFleu2012169_CR21","doi-asserted-by":"publisher","first-page":"9115","DOI":"10.1128\/MCB.25.20.9115-9126.2005","volume":"25","author":"GM Tannahill","year":"2005","unstructured":"Tannahill GM, Elliott J, Barry AC, Hibbert L, Cacalano NA, Johnston JA . SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signaling by accelerating SOCS3 degradation. Mol Cell Biol 2005; 25: 9115\u20139126.","journal-title":"Mol Cell Biol"},{"key":"BFleu2012169_CR22","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3109\/08977190903210954","volume":"27","author":"H Kiu","year":"2009","unstructured":"Kiu H, Greenhalgh CJ, Thaus A, Hilton DJ, Nicola NA, Alexander WS et al. Regulation of multiple cytokine signalling pathways by SOCS3 is independent of SOCS2. Growth Factors 2009; 27: 384\u2013393.","journal-title":"Growth Factors"},{"key":"BFleu2012169_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.cytogfr.2006.09.008","volume":"17","author":"E Rico-Bautista","year":"2006","unstructured":"Rico-Bautista E, Flores-Morales A, Fern\u00e1ndez-P\u00e9rez L . Suppressor of cytokine signaling (SOCS) 2, a protein with multiple functions. Cytokine Growth Factor Rev 2006; 17: 431\u2013439.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFleu2012169_CR24","doi-asserted-by":"publisher","first-page":"32953","DOI":"10.1074\/jbc.M600776200","volume":"281","author":"J Piessevaux","year":"2006","unstructured":"Piessevaux J, Lavens D, Montoye T, Wauman J, Catteeuw D, Vandekerckhove J et al. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem 2006; 281: 32953\u201332966.","journal-title":"J Biol Chem"},{"key":"BFleu2012169_CR25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cytogfr.2008.08.006","volume":"19","author":"J Piessevaux","year":"2008","unstructured":"Piessevaux J, Lavens D, Peelman F, Tavernier J . The many faces of the SOCS box. Cytokine Growth Factor Rev 2008; 19: 371\u2013381.","journal-title":"Cytokine Growth Factor Rev"},{"key":"BFleu2012169_CR26","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/35016611","volume":"405","author":"D Metcalf","year":"2000","unstructured":"Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000; 405: 1069\u20131073.","journal-title":"Nature"},{"key":"BFleu2012169_CR27","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1210\/mend.16.6.0845","volume":"16","author":"CJ Greenhalgh","year":"2002","unstructured":"Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, Adams TE et al. Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 2002; 16: 1394\u20131406.","journal-title":"Mol Endocrinol"},{"key":"BFleu2012169_CR28","doi-asserted-by":"publisher","first-page":"G472","DOI":"10.1152\/ajpgi.00218.2005","volume":"291","author":"CZ Michaylira","year":"2006","unstructured":"Michaylira CZ, Simmons JG, Ramocki NM, Scull BP, McNaughton KK, Fuller CR et al. Suppressor of cytokine signaling-2 limits intestinal growth and enterotrophic actions of IGF-I in vivo. Am J Physiol Gastrointest Liver Physiol 2006; 291: G472\u2013G481.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"BFleu2012169_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1198\/016214504000000683","volume":"99","author":"Z Wu","year":"2004","unstructured":"Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F . A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Assoc 2004; 99: 909\u2013917.","journal-title":"J Am Stat Assoc"},{"key":"BFleu2012169_CR30","first-page":"136","volume":"1","author":"RG Hawley","year":"1994","unstructured":"Hawley RG, Lieu FH, Fong AZ, Hawley TS . Versatile retroviral vectors for potential use in gene therapy. Gene Therapy 1994; 1: 136\u2013138.","journal-title":"Gene Therapy"},{"key":"BFleu2012169_CR31","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1084\/jem.189.9.1399","volume":"189","author":"S Li","year":"1999","unstructured":"Li S, Ilaria RLJ, Million RP, Daley GQ, Van Etten RA . The P190, P210, and P230 forms of the BCR\/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399\u20131412.","journal-title":"J Exp Med"},{"key":"BFleu2012169_CR32","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood-2009-05-217182","volume":"116","author":"H Agerstam","year":"2010","unstructured":"Agerstam H, J\u00e4r\u00e5s M, Andersson A, Johnels P, Hansen N, Lassen C et al. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood 2010; 116: 2103\u20132111.","journal-title":"Blood"},{"key":"BFleu2012169_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402\u2013408.","journal-title":"Methods"},{"key":"BFleu2012169_CR34","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/leu.2008.226","volume":"22","author":"H Quentmeier","year":"2008","unstructured":"Quentmeier H, Geffers R, Jost E, Macleod RA, Nagel S, Rohrs S et al. SOCS2: inhibitor of JAK2V617F-mediated signal transduction. Leukemia 2008; 22: 2169\u20132175.","journal-title":"Leukemia"},{"key":"BFleu2012169_CR35","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1089\/107999002760274863","volume":"22","author":"AG Jegalian","year":"2002","unstructured":"Jegalian AG, Wu H . Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 2002; 22: 853\u2013860.","journal-title":"J Interferon Cytokine Res"},{"key":"BFleu2012169_CR36","doi-asserted-by":"publisher","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","volume":"271","author":"RL Ilaria","year":"1996","unstructured":"Ilaria RL, Van Etten RA . P210 and P190(BCR\/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem 1996; 271: 31704\u201331710.","journal-title":"J Biol Chem"},{"key":"BFleu2012169_CR37","doi-asserted-by":"publisher","first-page":"40181","DOI":"10.1074\/jbc.C200450200","volume":"277","author":"CJ Greenhalgh","year":"2002","unstructured":"Greenhalgh CJ, Metcalf D, Thaus AL, Corbin JE, Uren R, Morgan PO et al. Biological evidence that SOCS-2 can act either as an enhancer or suppressor of growth hormone signaling. J Biol Chem 2002; 277: 40181\u201340184.","journal-title":"J Biol Chem"},{"key":"BFleu2012169_CR38","first-page":"247","volume":"13","author":"K Shuai","year":"1996","unstructured":"Shuai K, Halpern J, ten Hoeve J, Rao X, Sawyers CL . Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996; 13: 247\u2013254.","journal-title":"Oncogene"},{"key":"BFleu2012169_CR39","doi-asserted-by":"publisher","first-page":"35553","DOI":"10.1074\/jbc.274.50.35553","volume":"274","author":"PA Ram","year":"1999","unstructured":"Ram PA, Waxman DJ . SOCS\/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 1999; 274: 35553\u201335561.","journal-title":"J Biol Chem"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2012169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2012169","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2012169.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:03:36Z","timestamp":1684433016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,22]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["BFleu2012169"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.169","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,22]]}}}